Companies / Health Care / Biotechnology
Amgen stock buybacks
AMGN—No share repurchases in the company’s standard SEC financial data for the last twelve months.
Amgen’s filings haven’t reported share repurchases in standard form since Q4 2023.
Show as table
| Period | Value |
|---|---|
| Q3 '20 | $765M |
| Q4 '20 | $1.2B |
| Q1 '21 | $871M |
| Q2 '21 | $1.6B |
| Q3 '21 | $1.1B |
| Q4 '21 | $1.4B |
| Q1 '22 | $6.4B |
| Q2 '22 | $0 |
| Q3 '22 | $0 |
| Q4 '22 | $0 |
| Q1 '23 | $0 |
| Q2 '23 | $0 |
| Q3 '23 | $0 |
| Q4 '23 | $0 |
| Q1 '24 | $0 |
| Q2 '24 | $0 |
| Q3 '24 | $0 |
| Q4 '24 | $0 |
| Q1 '25 | $0 |
| Q2 '25 | $0 |
| Q3 '25 | $0 |
| Q4 '25 | $0 |
| Q1 '26 | $0 |
| Q2 '26 | $0 |
Show as table
| Period | Value |
|---|---|
| Q3 '20 | 589.0M |
| Q4 '20 | 585.0M |
| Q1 '21 | 581.0M |
| Q2 '21 | 576.0M |
| Q3 '21 | 570.0M |
| Q4 '21 | 565.0M |
| Q1 '22 | 551.0M |
| Q2 '22 | 537.0M |
| Q3 '22 | 538.0M |
| Q4 '22 | 538.0M |
| Q1 '23 | 538.0M |
| Q2 '23 | 537.0M |
| Q3 '23 | 538.0M |
| Q4 '23 | 539.0M |
| Q1 '24 | 536.0M |
| Q2 '24 | 541.0M |
| Q3 '24 | 542.0M |
| Q4 '24 | 545.0M |
| Q1 '25 | 541.0M |
| Q2 '25 | 541.0M |
| Q3 '25 | 542.0M |
| Q4 '25 | 544.0M |
| Q1 '26 | 544.0M |
| Q2 '26 | 544.0M |
$0last quarter (Q2 2026)
−$492Mnet of stock compensation ($492M)
+0.6%diluted shares, 1 year
−8.1%diluted shares, 5 years
$5.3Bdividends, 12 months
0%of free cash flow ($10.2B) spent on buybacks
$0raised by issuing stock, 12 months
$6.8Bleft under its authorization as of Jun 30, 2026
Amgen’s recent filings don’t report repurchases in the standard XBRL fields we read. That usually means it didn’t buy back stock, but some companies report buybacks only in custom fields. Check its latest 10-Q to be sure.
By fiscal year
Questions
- Does Amgen buy back its stock?
- Amgen’s filings haven’t reported share repurchases in standard form since Q4 2023.
- How much did Amgen spend on buybacks in fiscal 2025?
- $0, according to its 10-K for the fiscal year ending Dec 31, 2025.
- Is Amgen's share count going down?
- Its diluted share count changed −8.1% over five fiscal years and +0.6% over the last year.
- Does Amgen have a buyback authorization?
- Its filings show $6.8B remaining under its repurchase authorization as of Jun 30, 2026.
Latest filing used: 10-Q for the period ending Jun 30, 2026, filed Aug 5, 2026 · open on SEC.gov